Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.

Advances in pharmacology (San Diego, Calif.) - 1 Jan 2018

Cronin-Fenton Deirdre P, Damkier Per

Abstract excerpt

Tamoxifen reduces the rate of breast cancer recurrence by about one-half. It is converted to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome P450 2D6 (CYP2D6) and transported by ATP-binding cassette transporters. Genetic polymorphisms that confer reduced CYP2D6 activity or concurrent use of CYP2D6-inhibiting drugs may reduce the clinical efficacy of tamoxifen. The issue of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Drug Interactions
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Tamoxifen

Source

Identifiers

PMID: 29801584
DOI: 10.1016/bs.apha.2018.03.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.PMID 29801584Read ↗

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read ↗

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical RelevanceSemantic proximity Read ↗

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Semantic proximity Read ↗

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.Semantic proximity Read ↗

Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Semantic proximity Read ↗

CYP2D6 genotyping and the pharmacogenetics of tamoxifen.Semantic proximity Read ↗

Understanding CYP2D6 and its role in tamoxifen metabolism.Semantic proximity Read ↗

CYP2D6 polymorphisms and the impact on tamoxifen therapy.Semantic proximity Read ↗

CYP2D6 pharmacogenomics of tamoxifen treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.